Dysregulation of m6A modification and m6A-associated regulators likely plays a critical role in the initiation and progression of brain tumors21,61, and is supported by the evidence of reduced m6A levels in gliomas and inhibition of self-renewal of glioma stem cells (GSCs) by m6A writer METTL3 methylation of the ADAM19 transcript24,62. This evidence concerns the gene ADAM19 and central nervous system cancer.